Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker (BRKR) faces a permanent injunction in Delaware's U.S. District Court regarding its GeoMx products, following a patent infringement lawsuit by 10x Genomics. The Court will enter the injunction in January 2025, prohibiting Bruker from making, selling, or offering GeoMx Digital Spatial Profiler products in the United States.
The Court affirmed the $31 million damages from the November 2023 jury verdict, plus supplemental damages and interest. Notably, existing GeoMx users who installed instruments before November 18, 2023, can continue purchasing reagents for ongoing research. The jury found that the GeoMx products willfully infringed seven patents licensed to 10x Genomics by Prognosys.
Bruker announces the installation of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, jointly operated by the University of Basel, ETH Zürich, and the University of Zürich. This is Switzerland's second 1.2 GHz NMR, complementing existing equipment including an 800 MHz NMR in Basel.
The new instrument will enhance research capabilities in structural biology and macromolecular analysis, specifically enabling detailed studies of G protein-coupled receptors (GPCRs), intrinsically disordered proteins, and RNA research. The facility will support various applications including protein structure determination, dynamics measurement, ligand binding studies, and protein-protein interaction analysis.
Bruker (Nasdaq: BRKR) has launched the Dimension Nexus™ atomic force microscope (AFM) at the 2024 MRS Fall Meeting & Exhibit. This latest addition to the Dimension® AFM product line features the new-generation NanoScope® 6 controller and provides access to Bruker's exclusive PeakForce Tapping® technology along with over 50 AFM modes.
The small-footprint system is designed for both growing labs and multi-user facilities, offering upgradability and enhanced ease of use. The Dimension Nexus joins Bruker's successful product line, which has over 4,600 installations worldwide. Its compact and upgradable nature, combined with large-sample capabilities, makes it particularly suitable for multi-user laboratories where space and varying expertise levels are key considerations.
Bruker (BRKR) has announced a quarterly cash dividend payment of $0.05 per share on its common stock. The dividend will be distributed on December 16, 2024 to shareholders who are recorded as stockholders as of December 2, 2024. This decision was approved by the company's Board of Directors.
Bruker (BRKR) has announced its participation in three upcoming investor conferences. Executive Vice President & CFO Gerald Herman will represent the company at the Stifel 2024 Healthcare Conference in New York on November 18, the Wolfe Research 2024 Healthcare Conference in New York on November 19, and the Nasdaq 51st Investor Conference in London on December 10, 2024.
Live audiovisual webcasts will be available on Bruker's Investor Relations website, with replays accessible for 90 days after the events.
Bruker (NASDAQ: BRKR) has announced EpicIF, a breakthrough technology for their CellScape Spatial Proteomics platform. This enhancement expands compatible fluorophore conjugated antibodies by nearly 10-fold and increases throughput up to 2-fold while maintaining tissue integrity. The technology combines a proprietary reagent with visible light to erase fluorescence signals from almost any fluorophore.
Alongside EpicIF, Bruker is releasing new CellScape Navigator software with an improved user interface. Both upgrades will be available for existing CellScape instruments, offering enhanced flexibility in multiplexed immunofluorescence experiments and compatibility with additional fluorescent readouts like RNA-ISH.
Bruker (BRKR) reported Q3 2024 revenues of $864.4 million, up 16.4% year-over-year, with organic revenue growth of 3.1%. The company's GAAP diluted EPS was $0.27, while non-GAAP diluted EPS reached $0.60. Despite posting double-digit CER revenue growth, Bruker lowered its FY2024 guidance due to biopharma and China recovery delays. The updated guidance projects revenue between $3.34 to $3.37 billion, implying organic revenue growth of 3-4%, and non-GAAP EPS of $2.36-$2.41.
Bruker (Nasdaq: BRKR) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 5, 2024, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss results and business trends. Investors can access the webcast through the company's IR website and a slide presentation will be available. Pre-registration is available for expedited call access, and a replay will be accessible until December 5, 2024.
Bruker (Nasdaq: BRKR) announces significant advancements in 4D-Proteomics at the 23rd Human Proteome Organization World Congress. Key developments include:
1. Enhanced specificity and proteome coverage using diagonal-PASEF.
2. Achievement of a one-hundred dollar deep, high-accuracy plasma proteome analysis.
3. Introduction of high-sensitivity plasma glycopeptide analysis on timsTOF Ultra 2.
4. Increased peptide and protein identifications with ML-enhanced TIMSrescore.
5. Introduction of multiomics visualization and insights for proteomics and metabolomics.
These advancements enable robust, unbiased, and affordable proteomics with high-specificity protein identification and quantification, suitable for large-scale plasma proteomics studies.
Bruker (Nasdaq: BRKR) announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the '928 Patent') asserted by 10x Genomics against NanoString's CosMx® Spatial Molecular Imager (SMI) products in Europe. This ruling follows a similar decision by the German Federal Patent Court in May 2024, which declared the patent invalid in Germany. The UPC's decision extends the invalidation to France and The Netherlands.
The ruling is subject to appeal. Bruker awaits an additional hearing on a related patent (European Patent 4108782B1) and expects it to be declared invalid as well. The European Patent Office has issued a preliminary opinion considering this patent invalid, with a hearing scheduled for March 18, 2025.